Dissociated induction of cytotoxicity and DTH by CFA and CpG

Journal of Immunotherapy

Volumn 32, Issue 4, 2009, Pages 389-398

  Tigno Aranjuez, Justine T ^a   Lehmann, Paul V ^a,b   Tary Lehmann, Magdalena ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b Cellular Technology Limited   (United States)

Author keywords

Cytokines; Cytotoxic T cells; T cells; Th1 Th2 cells; Vaccination

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; DINUCLEOTIDE; FREUND ADJUVANT; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 2; CPG OLIGONUCLEOTIDE; CPG-OLIGONUCLEOTIDE; IMMUNOLOGICAL ADJUVANT; OLIGODEOXYRIBONUCLEOTIDE; OVA 8; OVA-8; OVALBUMIN; PEPTIDE FRAGMENT; PROTEIN; SUBUNIT VACCINE; UTY PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DELAYED HYPERSENSITIVITY; DRUG INHIBITION; DRUG MECHANISM; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; COMPARATIVE STUDY; DRUG EFFECT; IMMUNOLOGY; METABOLISM; PATHOLOGY; SKIN;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; FREUND'S ADJUVANT; HYPERSENSITIVITY, DELAYED; INTERFERON-GAMMA; INTERLEUKIN-17; INTERLEUKIN-2; MICE; MICE, INBRED C57BL; OLIGODEOXYRIBONUCLEOTIDES; OVALBUMIN; PEPTIDE FRAGMENTS; PROTEINS; SKIN; VACCINES, SUBUNIT;

EID: 67449085970     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31819d79a7     Document Type: Article

References (107)

1. Carter LL, Dutton RW. Type 1 and type 2: a fundamental dichotomy for all T-cell subsets. Curr Opin Immunol. 1996; 8:336-342.
2. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today. 1996;17:138-146.
3. - cells that make TH2 cytokines and help B cells. Science. 1993;260:1802-1805.
4. + T cells showing B cell helper function and reduced cytolytic activity in human immunodeficiency virus type 1 infection. J Exp Med. 1994; 180:489-495.
5. Salgame P, Abrams JS, Clayberger C, et al. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science. 1991;254:279-282.
6. + T cell clones: control of X4 and R5 HIV strain replication. J Clin Immunol. 2004;24:272-280.
7. + T cells secreting Th1 or Th2 cytokines. Immunity. 1995;2:271-279.
8. Croft M, Carter L, Swain SL, et al. Generation of polarized antigen-specific CD8 effector populations: reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J Exp Med. 1994; 180:1715-1728.
9. + regulatory thymocytes. Blood. 2003;102:4107-4114.
10. Gilliet M, Liu YJ. Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J Exp Med. 2002;195:695-704.
11. + regulatory T cells in the maintenance of T cell homeostasis. J Exp Med. 2004;200:1123-1134.
12. + regulatory T cells in human ovarian carcinoma. Cancer Res. 2005;65:5020-5026.
13. Park H, Li Z, Yang XO, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005;6:1133-1141.
14. Stumhofer JS, Laurence A, Wilson EH, et al. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat Immunol. 2006;7:937-945.
15. Sutton C, Brereton C, Keogh B, et al. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J Exp Med. 2006;203:1685-1691.
16. Vanden Eijnden S, Goriely S, De Wit D, et al. IL-23 upregulates IL-10 and induces IL-17 synthesis by polyclonally activated naive T cells in human. Eur J Immunol. 2005;35: 469-475.
17. Klein JR, Raulet DH, Pasternack MS, et al. Cytotoxic T lymphocytes produce immune interferon in response to antigen or mitogen. J Exp Med. 1982;155:1198-1203.
18. Raez LE, Cassileth PA, Schlesselman JJ, et al. Induction of CD8 T-cell-Ifn-gamma response and positive clinical outcome after immunization with gene-modified allogeneic tumor cells in advanced non-small-cell lung carcinoma. Cancer Gene Ther. 2003;10:850-858.
19. Pass HA, Schwarz SL, Wunderlich JR, et al. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. Cancer J Sci Am. 1998; 4:316-323.
20. + T cell immune response against a V3 loop multiepitope polypeptide (TAB 13) of HIV-1 Env after priming with purified fusion protein and booster with modified vaccinia virus Ankara (MVA-TAB) recombinant: a comparison of humoral and cellular immune responses with the vaccinia virus Western Reserve (WR) vector. Vaccine. 2001; 20:961-971.
21. Wang F, Bade E, Kuniyoshi C, et al. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin Cancer Res. 1999;5: 2756-2765.
22. Scheibenbogen C, Romero P, Rivoltini L, et al. Quantitation of antigen-reactive T cells in peripheral blood by IFNgamma-ELISPOT assay and chromium-release assay: a four-centre comparative trial. J Immunol Methods. 2000;244:81-89.
23. Russell ND, Hudgens MG, Ha R, et al. Moving to human immunodeficiency virus type 1 vaccine efficacy trials: defining T cell responses as potential correlates of immunity. J Infect Dis. 2003;187:226-242.
24. Slingluff CL Jr, Yamshchikov G, Neese P, et al. Phase I trial of a melanoma vaccine with gp100 (280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res. 2001;7:3012-3024.
25. Asai T, Storkus WJ, Whiteside TL. Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines. Clin Diagn Lab Immunol. 2000;7:145-154.
26. Scheibenbogen C, Lee KH, Stevanovic S, et al. Analysis of the T cell response to tumor and viral peptide antigens by an IFNgamma-ELISPOT assay. Int J Cancer. 1997;71:932-936.
27. Pecher G, Haring A, Kaiser L, et al. Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial. Cancer Immunol Immunother. 2002;51:669-673.
28. Evans TG, Kallas EG, Campbell M, et al. Evaluation of canarypox-induced CD8(+) responses following immunization by measuring the effector population IFNgamma production. Immunol Lett. 2001;77:7-15.
29. Ledford H. HIV vaccine may raise risk. Nature. 2007;450:325.
30. Gabrielsson S, Brichard V, Dhellin O, et al. IFN-gamma responses in peptide-treated melanoma patients measured by an ELISPOT assay using allogeneic dendritic cells. Anticancer Res. 2004;24:171-177.
31. Wei Y, Sticca RP, Holmes LM, et al. Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses. Int J Oncol. 2006;28:585-593.
32. Nagorsen D, Thiel E. Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer. Clin Cancer Res. 2006;12:3064-3069.
33. Pantaleo G. HIV-1 T-cell vaccines: evaluating the next step. Lancet Infect Dis. 2008;8:82-83.
34. Cohen J. AIDS research. Did Merck's failed HIV vaccine cause harm? Science. 2007;318:1048-1049.
35. Kleen TO, Asaad R, Landry SJ, et al. Tc1 effector diversity shows dissociated expression of granzyme B and interferon-gamma in HIV infection. AIDS. 2004;18:383-392.
36. Trapani JA, Smyth MJ. Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol. 2002;2:735-747.
37. Barry M, Bleackley RC. Cytotoxic T lymphocytes: all roads lead to death. Nat Rev Immunol. 2002;2:401-409.
38. Andersen MH, Schrama D, Thor Straten P, et al. Cytotoxic T cells. J Invest Dermatol. 2006;126:32-41.
39. Mosmann TR, Li L, Sad S. Functions of CD8 T-cell subsets secreting different cytokine patterns. Semin Immunol. 1997;9: 87-92.
40. Cher DJ, Mosmann TR. Two types of murine helper T cell clone. II. Delayed-type hypersensitivity is mediated by TH1 clones. J Immunol. 1987; 138:3688-3694.
41. Mielke ME, Ehlers S, Hahn H. T-cell subsets in delayed-type hypersensitivity, protection, and granuloma formation in primary and secondary Listeria infection in mice: superior role of Lyt-2+ cells in acquired immunity. Infect Immun. 1988;56:1920-1925.
42. + IL-17-producing T cells are important in effector functions for the elicitation of contact hypersensitivity responses. J Immunol. 2006;177: 6852-6858.
43. Nakae S, Komiyama Y, Nambu A, et al. Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity. 2002;17:375-387.
44. Janeway CA Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol. 1989;54(Pt 1):1-13.
45. Means TK, Lien E, Yoshimura A, et al. The CD14 ligands lipoarabinomannan and lipopolysaccharide differ in their requirement for Toll-like receptors. J Immunol. 1999;163: 6748-6755.
46. Abel B, Thieblemont N, Quesniaux VJ, et al. Toll-like receptor 4 expression is required to control chronic Mycobacterium tuberculosis infection in mice. J Immunol. 2002; 169:3155-3162.
47. Reiling N, Holscher C, Fehrenbach A, et al. Cutting edge: Toll-like receptor (TLR)2- and TLR4-mediated pathogen recognition in resistance to airborne infection with Mycobacterium tuberculosis. J Immunol. 2002;169: 3480-3484.
48. Aliprantis AO, Yang RB, Mark MR, et al. Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2. Science. 1999;285:736-739.
49. Vignal C, Guerardel Y, Kremer L, et al. Lipomannans, but not lipoarabinomannans, purified from Mycobacterium chelonae and Mycobacterium kansasii induce TNF-alpha and IL-8 secretion by a CD14-toll-like receptor 2-dependent mechanism. J Immunol. 2003;171:2014-2023.
50. Gilleron M, Quesniaux VF, Puzo G. Acylation state of the phosphatidylinositol hexamannosides from Mycobacterium bovis bacillus Calmette Guerin and mycobacterium tuberculosis H37Rv and its implication in Toll-like receptor response. J Biol Chem. 2003;278:29880-29889.
51. Sun S, Kishimoto H, Sprent J. DNA as an adjuvant: capacity of insect DNA and synthetic oligodeoxynucleotides to augment T cell responses to specific antigen. J Exp Med. 1998; 187:1145-1150.
52. Yamamoto S, Yamamoto T, Shimada S, et al. DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. Microbiol Immunol. 1992;36:983-997.
53. Bauer S, Kirschning CJ, Hacker H, et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci USA. 2001;98: 9237-9242.
54. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature. 2000;408:740-745.
55. Chu RS, Targoni OS, Krieg AM, et al. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med. 1997;186:1623-1631.
56. Rosato A, Zoso A, Milan G, et al. Individual analysis of mice vaccinated against a weakly immunogenic self tumorspecific antigen reveals a correlation between CD8 T cell response and antitumor efficacy. J Immunol. 2003;171: 5172-5179.
57. + T cell parameters. J Immunol. 2006;176:1999-2006.
58. Morris AG, Lin YL, Askonas BA. Immune interferon release when a cloned cytotoxic T-cell line meets its correct influenzainfected target cell. Nature. 1982;295:150-152.
59. Jassoy C, Harrer T, Rosenthal T, et al. Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes release gamma interferon, tumor necrosis factor alpha (TNF-alpha), and TNF-beta when they encounter their target antigens. J Virol. 1993;67:2844-2852.
60. Lee KH, Panelli MC, Kim CJ, et al. Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination. J Immunol. 1998;161: 4183-4194.
61. Peterson AC, Harlin H, Gajewski TF. Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J Clin Oncol. 2003;21:2342-2348.
62. Keene JA, Forman J. Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J Exp Med. 1982; 155:768-782.
63. Lanzavecchia A. Immunology. Licence to kill. Nature. 1998; 393:413-414.
64. Schoenberger SP, Toes RE, van der Voort EI, et al. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 1998;393:480-483.
65. + T-helper and a T-killer cell. Nature. 1998;393:474-478.
66. Bennett SR, Carbone FR, Karamalis F, et al. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature. 1998;393:478-480.
67. + T cell memory. Science. 2002;297:2060-2063.
68. Lu Z, Yuan L, Zhou X, et al. CD40-independent pathways of T cell help for priming of CD8(+) cytotoxic T lymphocytes. J Exp Med. 2000;191:541-550.
69. + T cell responses in the absence of CD4+ T cells. J Immunol. 2005;174:710-717.
70. + T cells are required for secondary expansion and memory in CD8 + T lymphocytes. Nature. 2003;421:852-856.
71. + T-cell memory via TRAIL-mediated activation-induced cell death. Nature. 2005;434: 88-93.
72. + memory T cells. Immunol Rev. 2006;211:146-153.
73. Di Rosa F, Matzinger P. Long-lasting CD8 T cell memory in the absence of CD4 T cells or B cells. J Exp Med. 1996; 183:2153-2163.
74. Marzo AL, Vezys V, Klonowski KD, et al. Fully functional memory CD8 T cells in the absence of CD4 T cells. J Immunol. 2004;173:969-975.
75. Wodarz D, Jansen VA. The role of T cell help for anti-viral CTL responses. J Theor Biol. 2001;211:419-432.
76. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21:335-376.
77. Roberts TL, Sweet MJ, Hume DA, et al. Cutting edge: species-specific TLR9-mediated recognition of CpG and non-CpG phosphorothioate-modified oligonucleotides. J Immunol. 2005;174:605-608.
78. Kawai T, Akira S. Innate immune recognition of viral infection. Nat Immunol. 2006;7:131-137.
79. Kawai T, Akira S. Antiviral signaling through pattern recognition receptors. J Biochem. 2007; 141:137-145.
80. Beste DJ, Peters J, Hooper T, et al. Compiling a molecular inventory for Mycobacterium bovis BCG at two growth rates: evidence for growth rate-mediated regulation of ribosome biosynthesis and lipid metabolism. J Bacteriol. 2005; 187: 1677-1684.
81. Lee KW, Jung J, Lee Y, et al. Immunostimulatory oligodeoxynucleotide isolated from genome wide screening of Mycobacterium bovis chromosomal DNA. Mol Immunol. 2006;43:2107-2118.
82. Ghosh TK, Mickelson DJ, Solberg JC, et al. TLR-TLR cross talk in human PBMC resulting in synergistic and antagonistic regulation of type-1 and 2 interferons, IL-12 and TNF-alpha. Int Immunopharmacol. 2007;7:1111-1121.
83. Clatch RJ, Lipton HL, Miller SD. Characterization of Theiler's murine encephalomyelitis virus (TMEV)-specific delayed-type hypersensitivity responses in TMEV-induced demyelinating disease: correlation with clinical signs. J Immunol. 1986; 136:920-927.
84. McRae BL, Kennedy MK, Tan LJ, et al. Induction of active and adoptive relapsing experimental autoimmune encephalomyelitis (EAE) using an encephalitogenic epitope of proteolipid protein. J Neuroimmunol. 1992;38: 229-240.
85. Ando DG, Clayton J, Kono D, et al. Encephalitogenic T cells in the B10.PL model of experimental allergic encephalomyelitis (EAE) are of the Th-1 lymphokine subtype. Cell Immunol. 1989;124:132-143.
86. Baron JL, Madri JA, Ruddle NH, et al. Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma. J Exp Med. 1993;177:57-68.
87. ClinicalTrials.gov (database online). Bethesda, MD. National Institutes of Health, Department of Health and Human Services, National Library of Medicine. Updated September 20, 2007.
88. + T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest. 2005; 115:739-746.
89. Olbrich C, Muller RH, Tabatt K, et al. Stable biocompatible adjuvants - a new type of adjuvant based on solid lipid nanoparticles: a study on cytotoxicity, compatibility and efficacy in chicken. Altern Lab Anim. 2002;30:443-458.
90. Baral RN, Saha A, Chatterjee SK, et al. Immunostimulatory CpG oligonucleotides enhance the immune response of anti-idiotype vaccine that mimics carcinoembryonic antigen. Cancer Immunol Immunother. 2003;52:317-327.
91. Drogoz A, Munier S, Verrier B, et al. Towards biocompatible vaccine delivery systems: interactions of colloidal PECs based on polysaccharides with HIV-1 p24 antigen. Biomacromolecules. 2008;9:583-591.
92. Hoft DF. Tuberculosis vaccine development: goals, immunological design, and evaluation. Lancet. 2008;372:164-175.
93. Qin HY, Chaturvedi P, Singh B. In vivo apoptosis of diabetogenic T cells in NOD mice by IFN-gamma/TNF-alpha. Int Immunol. 2004;16:1723-1732.
94. Kukreja A, Costi G, Marker J, et al. NKT cell defects in NOD mice suggest therapeutic opportunities. J Autoimmun. 2002;19:117-128.
95. Serreze DV, Chapman HD, Post CM, et al. Th1 to Th2 cytokine shifts in nonobese diabetic mice: sometimes an outcome, rather than the cause, of diabetes resistance elicited by immunostimulation. J Immunol. 2001;166: 1352-1359.
96. Kelly CD, O'Loughlin C, Gelder FB, et al. Rapid generation of an anthrax immunotherapeutic from goats using a novel non-toxic muramyl dipeptide adjuvant. J Immune Based Ther Vaccines. 2007;5:11.
97. Wardowska A, Dzierzbicka K, Szarynska M, et al. Analogues of muramyl dipeptide (MDP) and tuftsin limit infection and inflammation in murine model of sepsis. Vaccine. 2009;27: 369-374.
98. Lemesre JL, Holzmuller P, Goncalves RB, et al. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial. Vaccine. 2007;25: 4223-4234.
99. Tagliabue A, Rappuoli R. Vaccine adjuvants: the dream becomes real. Hum Vaccines. 2008;4:347-349.
100. Schwarz TF. AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention. Expert Rev Vaccines. 2008;7:1465-1473.
101. Casella CR, Mitchell TC. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol Life Sci. 2008;65:3231-3240.
102. Ryll R, Kumazawa Y, Yano I. Immunological properties of trehalose dimycolate (cord factor) and other mycolic acid-containing glycolipids: a review. Microbiol Immunol. 2001;45:801-811.
103. Curtis MM, Way SS. Interleukin-17 in host defence against bacterial, mycobacterial and fungal pathogens. Immunology. 2009;126:177-185.
104. Radoja S, Frey AB, Vukmanovic S. T-cell receptor signaling events triggering granule exocytosis. Crit Rev Immunol. 2006;26:265-290.
105. + T cells limits their cytokine synthesis and proliferation. J Exp Med. 1996; 184:1543-1547.
106. Nicklas W. Aluminum salts. Res Immunol. 1992;143:489-494; discussion 574.
107. Lindblad EB. Aluminium compounds for use in vaccines. Immunol Cell Biol. 2004;82:497-505.